Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{184135,
        author = {Miss. Bhoomi B. Sagat},
        title = {Parkinson’s Disease: New Clinical Trials and Emerging Therapies – A Review.},
        journal = {International Journal of Innovative Research in Technology},
        year = {2025},
        volume = {12},
        number = {4},
        pages = {1801-1810},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=184135},
        abstract = {Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra, leading to motor symptoms such as bradykinesia, tremor, rigidity, and postural instability, along with a wide range of non-motor manifestations. The etiology of PD is multifactorial, involving genetic, environmental, and aging-related factors. Despite significant advances in understanding the disease pathology, there is currently no cure, and treatment remains primarily symptomatic. Pharmacological approaches, particularly levodopa-based therapies, remain the gold standard for symptom management, while adjunctive medications and surgical interventions like deep brain stimulation offer additional benefit in advanced stages. Recent developments in neuroprotective strategies, gene therapy, and stem cell research offer hope for disease-modifying treatments. This review provides a comprehensive overview of the pathophysiology, clinical features, current therapeutic strategies, and emerging treatments for Parkinson’s disease, emphasizing the need for continued research toward a cure and improved patient quality of life.},
        keywords = {},
        month = {September},
        }